Ignite Creation Date:
2024-05-06 @ 7:15 PM
Last Modification Date:
2024-10-26 @ 3:03 PM
Study NCT ID:
NCT05948462
Status:
WITHDRAWN
Last Update Posted:
2023-12-13
First Post:
2023-06-27
Brief Title:
Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive ALK Non-small Cell Lung Cancer NSCLC Who Progressed on Single-agent Lorlatinib
Sponsor:
SCRI Development Innovations LLC
Organization:
SCRI Development Innovations LLC